Previous 10 | Next 10 |
PASADENA, CA, July 18, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (Nasdaq: LIXT and LIXTW) (“LIXTE” or the “Company”) today announced it has entered into a securities purchase agreement with a single health-care focused, institutional investor for...
2023-07-17 13:40:37 ET Gainers: BridgeBio Pharma BBIO +78% . Acumen Pharmaceuticals ABOS +64% . GreenPower Motor Company GP +41% . Prestige Wealth PWM +39% . Quantum-Si incorporated ( QSI ) +35% . Lixte Biotechnology Holdings ( LIXT ) ...
Results Provide Striking Molecular Evidence that I nhibiting PP2A with LB -100 Sensitizes Cancer Cells to Immunotherapy and Chemotherapy PASADENA, CA, July 17, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (...
2023-06-23 08:58:45 ET LIXTE Biotechnology ( NASDAQ: LIXT ) said on Friday that it had received a Nasdaq notice on regaining compliance with stock exchange's minimum bid price requirement. The company was notified of non-compliance last year on June 24 with...
PASADENA, CA, June 23, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT ) (“LIXTE” or the “Company”) announced today that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has regained compl...
2023-06-16 14:00:02 ET Gainers: Evelo Biosciences ( EVLO ) +120% . Sientra ( SIEN ) +29% . TMC the metals company ( TMC ) +24% . ICZOOM Group ( IZM ) +20% . iRobot Corporation ( IRBT ) +20% . Marker Therapeutics ( MRKR ) ...
PASADENA, CA, June 07, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: L IXT ) (“LIXTE”), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced the en...
2023-06-02 14:49:11 ET LIXTE Biotechnology Holdings ( NASDAQ: LIXT ) has announced that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock effective on Friday, June 2, 2023. The Company’s common stock will trade on a post-split basi...
PASADENA, CA, June 02, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( Nasdaq: LIXT ) announced today that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock effective on Friday, ...
Results A dd to G rowing Body of E vidence that I nhibiting PP2A with LB - 100 M ay B e a General Method for Enhancing the Effectiveness of Immunotherapy in Refractory Cancers PASADENA, CA, May 30, 2023 (GLOB...
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...